Novartis Must Note Blood Pressure Drug Risks On EU Labels
A European regulator warned on Friday that Novartis AG's blood pressure drug Rasilez should not be prescribed to certain patients with Type 1 or Type 2 diabetes or kidney problems, and...To view the full article, register now.
Already a subscriber? Click here to view full article